FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
PCVX Financial Statements
Year
2024
2023
2022
2021
Current Assets
1.79B
1.1B
942.55M
256.35M
Cash & Short Term Investments
1.75B
1.08B
931.38M
245.97M
Cash And Cash Equivalents
387.88M
397.45M
834.66M
68.98M
Short Term Investments
1.36B
682.78M
96.72M
176.99M
Net Receivables
0
0
0
0
Inventory
0
0
-1M
-1.2M
Other Current Assets
40.78M
9.57M
0
0
Non-Current Assets
1.72B
311.96M
63.62M
67.99M
Property, Plant & Equipment
270.15M
110.62M
31.65M
35.91M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
1.39B
162.68M
26.55M
27.12M
Tax Assets
0
0
0
0
Other Non-Current Assets
65.68M
38.66M
5.43M
4.96M
Other Assets
0
0
0
0
Total Assets
3.51B
1.41B
1.01B
324.34M
-
-
-
-
Current Liabilities
140.18M
145.34M
40.52M
28.72M
Accounts Payable
48.45M
14.59M
9.79M
6.76M
Short Term Debt
5.89M
0
5.91M
5.28M
Tax Payables
0
0
0
0
Deferred Revenue
0
0
0
0
Other Current Liabilities
20.55M
11.06M
17.73M
7.95M
Total Current Liabilities
140.18M
145.34M
40.52M
28.72M
Total Non-Current Liabilities
65.32M
22.11M
12.04M
11.6M
Long-Term Debt
65.22M
0
0
0
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
100k
0
9k
96k
Total Liabilities
205.5M
167.45M
52.56M
40.32M
Other Liabilities
0
0
0
0
Stockholders Equity
3.31B
1.24B
953.61M
284.02M
Common Stock
128k
98k
82k
56k
Retained Earnings
-1.39B
-924.39M
-522.13M
-298.64M
Accumulated Other Comprehensive Income/Loss
-3.87M
179k
-361k
-241k
Other Shareholders Equity
4.7B
0
0
0
Total Liabilities and Stockholders Equity
3.51B
1.41B
1.01B
324.34M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-924.39M
-522.13M
-298.64M
-198.56M
Net Income
-463.93M
-402.27M
-239.64M
-100.08M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-1.39B
-924.39M
-522.13M
-298.64M
Other Distributions
-463.93M
-402.27M
-223.49M
-100.08M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
270.15M
110.62M
31.65M
35.91M
Annual Depreciation
0
3.16M
9.2M
1.8M
Capital Expenditure
-22.43M
-67.88M
-5.85M
-6.55M
Net PPE
292.57M
175.34M
28.3M
40.67M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
